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The  antigen  associated  with  most  cases  of  non-T,  non-B  acute  lymphoblastic 
leukemia,  as  first  described  by  Greaves  and  referred  to  as  the  common  acute 
lymphoblastic leukemia antigen (CALLA), is a  95,000-100,000-mol  wt surface mem- 
brane glycoprotein identified by both heteroantisera and monoclonal antibodies, J5, 
VIL-A 1, and BA-3 (1-5). Because of the occurrence of CALLA on the cells from most 
cases of non-T,  non-B  acute  lymphoblastic leukemia  (common  ALL), it  is a  useful 
marker for the diagnosis of this disorder. In addition, J5 antibody has been adminis- 
tered  as  passive serotherapy  in  common  ALL  (6).  Recently,  this  antigen  has  been 
detected on a  variety of other cell types including some normal bone marrow cells, as 
many  as  25%  of cases  of T  cell  acute  lymphoblastic leukemia  (T-ALL),  Burkitt's 
lymphoma,  follicular lymphoma,  normal renal tubular  and  glomerular epithelium, 
fetal small intestine, and breast myoepithelium  (7,  8).  During the course of investi- 
gations on the expression of CALLA in a  variety of human hematopoietic malignan- 
cies,  we  observed  reactivity  of  monoclonal  anti-CALLA  antibodies  with  normal 
polymorphonuclear neutrophils (PMN). This reactivity appears to be specific and not 
mediated  by  Fc  receptors.  Since  the  presence  of  CALLA  positive  cells  can  be 
considered  indicative of involvement  by lymphoma  or  leukemia,  the  expression  of 
CALLA by PMN could produce falsely positive results when CALLA is examined for 
in bone marrow aspirates, peripheral blood or other body fluids. 
Materials  and  Methods 
Cells.  PMN were isolated from the peripheral blood of 13 healthy normal adult volunteers. 
The granulocyte- and erythrocyte-rich fraction was separated by gradient centrifugation with 
Ficoll-Hypaque (Accurate Chemical & Scientific Corp., Westbury, NY)  (600 g, 30 min)  then 
mixed 1:1 with Plasma-Gel (HTI Corporation, Buffalo, NY)  for 30 min at 37°C to allow the 
erythrocytes to settle out. The granulocyte-rich supernatant was washed three times in medium 
RPMI  1640  (Gibco  Laboratories,  Grand  Island  Biological Co.,  Grand  Island,  NY)  and 
resuspended at  3 ×  10*/ml.  Purity of the preparations was documented morphologically on 
cytocentrifuge preparations. Cell lines studied included Raji (Burkitt's lymphoma), NALM-1 
(lymphoblast crisis of chronic myelogenous leukemia), MOLT-4 (T ALL), and HL60 (promye- 
locytic leukemia). The induction of HL60 cells to more mature myeloid cells was performed 
with dimethyl sulfoxide (DMSO)  (1.25%;  Microbiological Associates, Walkersville, MD) and 
12-tetradencanoyl-phorbol-13-acetate (TPA) (10 -s M; Sigma Chemical Co., St. Louis, MO) as 
previously described (9,  10). Cell suspensions were prepared from lymph nodes involved by 
follicular lymphoma (12 cases)  by pressing teased-out cells through a stainless steel mesh and 
washing in RPMI  1640. 
Irnmunostaining.  Indirect immunofluorescence was  performed by incubating 2  ×  105 ceils 
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with  100  /.tl of primary antibody or control  immunoglobulin  in  phosphate-buffered saline 
containing bovine serum albumin (2%) and sodium azide (0.2%) for 30 min on ice. After three 
washes, 100/tl of the fluorescein-conjugated, affinity-purified IgG fraction of goat anti-mouse 
IgG (1:40, Kirkegaard and Perry Co., Kensington, MD) was added for another 30 min on ice. 
Murine monoclonal anti-CALLA antibodies included (a) J5 in three forms (1/xg/ml): whole 
ascites and IgG-F(ab')2 (kindly provided by Dr. Jerome Ritz, Harvard University) and IgG 
fraction (Coulter Corp., Hialeah, FL); (b) BA-3 antibody (ascites, 1  : 100) (4, 5) (courtesy of Dr. 
Tucker Le Bien, University of Minnesota); and (c) VIL-A1 antibody (3) (courtesy of Dr. Walter 
Knapp, University of Vienna). Other monoclonal antibodies included OKM 1, OKT6 (Ortho 
Pharmaceuticals, Raritan, N  J), and Leu-1 (Becton, Dickinson & Co., Sunnyvale, CA); all were 
used at  1 /~g/ml. Additional controls included a series of nonreactive, purified murine mono- 
clonal (hybridoma) IgG proteins that were substituted for primary antibody and included one 
each of the IgG classes IgG1, IgG2a, IgG2b, and IgG3 (all at 30/xg/ml) (provided by Dr. Kenneth 
Schroer, National Institutes of Health). Nonreactive ascites from the IgGl-producing murine 
myeloma  P3  ×  63  (Bethesda  Research  Laboratories,  Rockville, MD),  was  also  used  as  a 
negative control. In some instances heat-inactivated (56°C, 30 minutes) normal human serum 
(1:4) or a human IgG1 myeloma protein (30/~g/ml, provided by Dr. Gerald Crabtree, National 
Institutes of Health) were added to PMN  (37°C, 30 min) before immunostaining. Cells were 
subsequently washed in ice-cold buffer and stained as described above. 
Fluorescence Detection.  Fluorescence was assayed on a fluorescence-activated  cell sorter (FACS- 
II, B-D FACS Systems, Becton, Dickinson & Co), at 500 mW of laser power (argon laser), 488 
nm wavelength, 630 V  photomultiplier tube sensitivity, and a fluorescence gain setting of 4 on 
a  scale of 16.  The data was recorded on a  PDP-11/34  computer  (Digital Electronic Corp., 
Marlboro, MA),  1023-channel  histograms were generated and  the percentage of fluorescent 
cells as  well  as  the  mean  fluorescence  intensity  (mean  channel  number)  were  calculated. 
Fluorescence microscopy was performed on a  Leitz Orthoplan equipped with epifluorescence 
at 450-490 nm excitation and 515 nm suppression filters. 
Immunoprecipitation  and Gel Electrophoresis.  Cell surface membrane proteins or intact cells were 
labeled  with  125I using  laetoperoxidase and  hydrogen  peroxide  (11).  The  cells  were  then 
solubilized in 10 mM TRIS buffer (pH 7.4) containing 0.14 M NaCI, 1% Triton-x-100, and 100 
/lg/ml phenylmethylsulfonyl fluoride. After centrifugation, these cellular extracts were then 
immunoprecipitated with J5 (2/~g/5-10 ×  106 cells) and analyzed by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) as described previously (I 1). Parallel control 
immunoprecipitations were also performed with UPC10, a nonreactive murine IgG2a (Litton 
Bionetics, Bethesda, MD). 
Results 
The granulocyte fraction from all normal individuals tested stained with J5, VIL- 
A1,  and  BA-3  (mean  89%,  range  55-99%).  All  three  preparations  of J5,  namely, 
ascites, intact IgG, and F(ab')2, reacted with granulocytes (Fig.  1 A, B). Greater than 
90%  of cells stained with  OKM1,  however,  no  fluorescence was  observed  with  the 
nonreactive  mouse  ascites,  purified  murine  IgG1,  IgG2a,  IgG2b,  IgG3,  antibodies 
OKT6  and Leu-1, or after omission of primary antibody. Further, preincubation of 
cells with normal human  serum or human  IgG1  did not affect either the percentage 
of cells stained by J5 or the intensity of fluorescence (Fig. 1 C). To determine whether 
anti-CALLA  antibody  could  distinguish  between  neutrophils  and  eosinophils,  the 
leukocytes from normal individuals and from a  patient with hypereosinophilia were 
stained  with  the  F(ab')2  fraction  of J5  and  sorted  into  fluorescent-positive  and 
-negative fractions on  the  FACS.  The  cells were  collected, cytocentrifuged, stained 
with  Wright's stain,  and  differential counts  were  performed.  The  positive fractions 
were greatly enriched for PMN  (95 and  100%  for normals and 86%  for the hypereo- 
sinophilia patient),  whereas  the negative  fractions were  predominantly eosinophils, 
lymphocytes, and monocytes. The fluorescence intensity of neutrophils stained with 1066  COSSMAN ET AL.  BRIEF DEFINITIVE  REPORT 
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FIG.  1.  (A) J5 staining of granulocytes as compared with control (murine IgG2a) shows 98% of 
cells stained. Linear scale. (B)  Log transformation of histogram from A amplifies the positive 
staining reaction of granulocytes with J5. Log scale (two decades). (C) Granulocytes and follicular 
lymphoma had comparable fluorescence intensity when stained with J5. These granulocytes were 
pretreated with normal human serum and showed no diminution of fluorescence intensity when 
stained with J5.  Preincubation with human IgG1 myeloma protein or staining with the F(ah')2 
fraction of j5 showed similar fluorescence (not shown). The small negative peak in the granulocyte 
fraction was sorted and proved to be largely eosinophils.  Linear scale. (D) The Burkitt's lymphoma 
ceil line, Raji, and a common ALL cell line, NALM-1, reacted with  J5 and the relative intensity of 
the fluorescence  was greater than that of granulocytes. Linear scale, The control in all cases was a 
murine IgG~ monoctonal protein. All other negative controls produced similar results (see text). 
Each curve includes I0,000 cells counted. 
j5 was comparable to that observed with follicular lymphoma cells but less than that 
found with  Raji cells  (mean channel  160)  and NALM-1  cells  (mean channel  180) 
(Fig.  1 D). The average mean fluorescence channel was 83 for PMN (10 samples) and 
102  for follicular lymphomas (12 samples). IgG-J5 also reacted with HL60; however, 
this interaction appeared to be mediated through Fc receptors since (a)  staining was 
inhibited by preincubation with human serum or human IgG1 myeloma protein, and 
(b)  F(ab')2 J5  did not react with HL60. Addition of either TPA or DMSO to HL60 
cells did not result in induction of specific J5 reactivity during a  5-d course. 
The  membrane determinant detected  on  PMN  by  anti-CALLA antibodies was 
biochemically characterized by cell surface labeling, immunoprecipitation, and SDS- 
PAGE gel electrophoresis. Autoradiographs of these gels demonstrated that J5  anti- 
body identified a protein on the cell surface of PMN of ~95,000-110,000 mol wt, and 
was similar in size to that found on Raji cells (95,000-100,000 mol wt)  (Fig. 2). These 
proteins recognized by J5  were not present in immunoprecipitates performed with 
control  UPC10  IgG2a  monoclonal antibodies or  on  the  T  cell  leukemia cell  line, 
MOLT-4. 
Discussion 
These studies demonstrate that the anti-CALLA monoclonal antibodies, J5, VIL- 
A1, and BA-3 consistently react with human polymorphonuclear neutrophils but not COSSMAN  ET AL.  BRIEF  DEFINITIVE REPORT  1067 
FIG. 2.  SDS-PAGE analysis of lzSI-surface-labeled cells after  immunoprecipitation.  Molecular 
weight standards  are  shown in  the  left lane. PMN  (a,  b),  Raji  (c, d),  and  Molt-4 (e,  f)  were 
immunoprecipltated with a nonreactive murine IgG2a 0JPC10) (a, c, e) or j5 (b, d, f). From PMN, 
J5 immunopreeipitated  a single band that  has a  molecular weight similar to that of the band 
obtained  with Raji cells. These proteins were not immunoprecipitated  with Molt-4 cells or with 
UPC 10 monoclonal antibodies. 
with other leukocytes. This reactivity does not appear to be mediated by cell surface 
Fc  receptors  since  staining  persisted  after  saturation  of these  receptors  with  either 
human  IgG1  myeloma  protein  or  normal  human  serum.  Furthermore,  the  F(ab')2 
fraction and  the  intact  IgG form of J5  showed equivalent  reactivity.  Other  routine 
IgG2a antibodies,  including Leu-1, did not react with  granulocytes.  Preparative  cell 
sorting  of J5-positive  and  -negative  fractions  indicated  that  the  J5-positive  cells 
observed  among  granulocytes  and  unseparated  peripheral  blood  leukocytes  were, 
indeed,  PMN. 
The antigen detected on the cell membrane of PMN was similar in size to CALLA 
present  on Raji  cells  (95,000-110,000  tool wt  for PMN  and  95,000-100,000  mol wt 
for Raji)  and was immunostained  by three  different  anti-CALLA antibodies.  Thus, 
the  antigen  detected  on  PMN  not only shares  an  epitope  with  CALLA, but  these 
antigens  may be  identical.  Although  blasts  from  the  lymphoblast  crisis  of chronic 
myelogenous leukemia  (CML)  are frequently CALLA-positive (2, 4, 7), CALLA may 
not be expressed  on myeloid precursor cells since;  (a)  the cells of the stable phase of 
CML  are  reported  to  lack  CALLA  (7);  (b)  anti-CALLA  (J5)  treatment  does  not 
inhibit  proliferation  in myeloid clonal assays (12); and  (c) as observed in the present 
study, the promyelocytic leukemia cell line,  HL60, did not specifically stain with J5. 
Thus, CALLA appears to be acquired at a late stage of PMN differentiation. Although 
anti-CALLA  antibodies  have  a  role  in  the  diagnosis  of lymphoma  and  leukemia, 
admixed  PMN  in patient  samples could masquerade  as CALLA-positive malignant 
cells.  As an  example,  the  pleural  effusion  from a  patient  with  follicular  lymphoma 1068  COSSMAN  ET AL.  BRIEF DEFINITIVE REPORT 
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Fro. 3.  Dot  plot display of FACS-II analysis of a  pleural  fluid from  a  patient with  follicular 
lymphoma stained with J5. A cluster of large, stained cells is seen in the upper right. This stained 
cell population was sorted and was found to consist of polymorphonuclear  neutrophils. 
contained 6% J5-stained cells (Fig. 3). This result was initially interpreted as indicating 
a  low  level of involvement  by the neoplastic process.  However,  when  these stained 
cells  were  sorted  on  the  FA(3S,  they  proved  to  be  entirely  composed  of  PMN. 
Therefore,  caution  should  be exercised when  studying effusions, bone  marrow  aspi- 
rates,  and  especially unseparated  leukocyte  buffy  coats  as  has  been  suggested  for 
immunofluorescence analysis by flow cytometry (13). 
Summary 
Monoclonal antibodies J5,  VIL-A1, and  BA-3, known  to react with  the common 
acute  lymphoblastic  leukemia  antigen  (CALLA)  were  found  to  specifically stain 
normal  human  polymorphonuclear  neutrophils  (PMN).  The  antigen  detected  on 
PMN  had  a  molecular  weight  (95,000-110,000  mol  wt)  close  to  that  of CALLA 
(95,000-100,000  mol wt) and thus these surface membrane antigens are likely related, 
if not  identical. The  fluorescent staining intensity of PMN  is comparable to that  of 
CALLA-positive leukemic cells and  the presence of PMN  in  patient  samples could 
potentially produce false-positive results in diagnosis. 
Received  for publication 13 December 1983. 
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